Key clinical point: The efficacy and safety of eptinezumab in preventing migraine realized in the PROMISE-1 and PROMISE-2 trials remain unperturbed by the intrinsic baseline characteristics of the study participants, including sex, age, and body mass index (BMI).
Main finding: The ≥50% migraine responder rate (MRR) was ≥10% higher with eptinezumab relative to placebo for most demographic factors, except in the case of obesity; although patients with a BMI of 30-35 kg/m 2 receiving eptinezumab vs. placebo showed improved ≥50% MRR, the separation was <10%. Eptinezumab was generally safe, and no new treatment-emergent adverse events were identified.
Study details: This was a post hoc subgroup analysis of adult patients with episodic or chronic migraine from the phase 3 PROMISE-1 and PROMISE-2 trials, respectively, which included a total of 1,960 patients in the safety analysis and 1,737 patients (99.8%) in the efficacy analysis.
Disclosures: The study received financial support from H. Lundbeck A/S. The authors disclosed having no conflicts of interest.
Source: Martin V et al. Clin Ther. 2022 (Feb 9). Doi: 10.1016/j.clinthera.2022.01.006